Inventor · disambiguated record
Heiko Schuster
Also filed as: SCHUSTER HEIKO
156 granted patents·93 pending applications·167 citations·filing 2012–2025
99Inventor score
Files withIMMATICS BIOTECHNOLOGIES GMBH243AMGEN INC2EVONIK INDUSTRIES AG1EVONIK TECHNOCHEMIE GMBH1IMMATICS US INC1
Top patents by PatentIndex Score
249 records- 0199US11278571B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Mar 22, 2022·8 cites·20 claims
- 0299US11246889B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 15, 2022·5 cites·20 claims
- 0399US11071756B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 27, 2021·5 cites·20 claims
- 0499US10899810B2B*44 restricted peptides for use in immunotherapy against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·6 cites·20 claims
- 0599US10888587B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 12, 2021·8 cites·20 claims
- 0699US10881690B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 5, 2021·8 cites·20 claims
- 0799US10869897B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Dec 22, 2020·8 cites·20 claims
- 0899US10722538B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 28, 2020·8 cites·20 claims
- 0998US11732021B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Aug 22, 2023·3 cites·20 claims
- 1098US11655281B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted May 23, 2023·3 cites·20 claims
- 1198US11655280B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted May 23, 2023·2 cites·20 claims
- 1298US11603397B2Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Mar 14, 2023·2 cites·20 claims
- 1398US11214608B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jan 4, 2022·6 cites·20 claims
- 1498US11117941B2B*44 restricted peptides for use in immunotherapy against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Sep 14, 2021·3 cites·20 claims
- 1598US11078253B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Aug 3, 2021·5 cites·20 claims
- 1698US11053296B2Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 6, 2021·5 cites·20 claims
- 1798US10899811B2B*44 restricted peptides for use in immunotherapy against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·5 cites·20 claims
- 1898US10772915B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Sep 15, 2020·5 cites·20 claims
- 1998US10695374B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 30, 2020·5 cites·26 claims
- 2098US10639332B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted May 5, 2020·8 cites·20 claims
- 2197US11248035B1Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Feb 15, 2022·3 cites·20 claims
- 2297US10709738B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jul 14, 2020·3 cites·20 claims
- 2397US9889159B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Feb 13, 2018·16 cites·22 claims
- 2496US10639331B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted May 5, 2020·8 cites·20 claims
- 2596US10568909B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Feb 25, 2020·8 cites·20 claims
- 2696US10463696B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2017·Granted Nov 5, 2019·11 cites·20 claims
- 2795US11020433B2Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jun 1, 2021·2 cites·20 claims
- 2892US11819518B2Peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Nov 21, 2023·1 cites·20 claims
- 2992US2025092104A1Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methodsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 3091US12318407B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Jun 3, 2025·0 cites·20 claims
- 3191US12290530B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted May 6, 2025·0 cites·20 claims
- 3291US12285443B2Peptides displayed by HLA for use immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Apr 29, 2025·0 cites·20 claims
- 3391US12274716B2Peptides displayed by HLA for use immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Apr 15, 2025·0 cites·20 claims
- 3491US12257269B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Mar 25, 2025·0 cites·20 claims
- 3591US12246039B2Peptides displayed by HLA for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Granted Mar 11, 2025·0 cites·20 claims
- 3691US2023285461A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3791US2023285462A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 3890US11840577B2Antigen binding proteins specifically binding MAGE-AIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Dec 12, 2023·2 cites·9 claims
- 3990US2024239865A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4090US2024166713A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4190US2024166717A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4290US2024239866A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4390US2024166715A1Amidated peptides and their deamidated counterparts displayed by non-hla-a*02 for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4490US2023241109A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 4590US2024307447A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4690US2023241112A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 4790US2023241113A1Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
- 4890US2024269183A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 4990US2024374642A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
- 5090US2024358757A1Peptides displayed by hla for use in immunotherapy against different types of cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2024·Application pending·0 cites
Showing the top 50 of 249 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Heiko Schuster files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →